2.Connotation of distal bleeding based on modern pathophysiological mechanism and application of Huangtu Decoction for acute coronary syndrome complicated with acute upper gastrointestinal hemorrhage in critical care medicine.
China Journal of Chinese Materia Medica 2023;48(10):2583-2594
Huangtu Decoction, first recorded in Essentials from the Golden Cabinet(Jin Kui Yao Lue) from ZHANG Zhong-jing in Han dynasty, is used to treat distal bleeding. It is mainly treated for the syndrome of failing to control blood with spleen-yang deficiency. The connotation of distal bleeding is more extensive, including not only upper gastrointestinal bleeding in the traditional sense such as peptic ulcer bleeding, gastrointestinal tumors, gastric mucosal lesions, vascular dysplasia, esophagogastric variceal bleeding, and pancreatic and biliary tract injury, but also other anorectal diseases such as part colon and rectal cancer swelling or polyps, hemorrhoids, and anal fissure and other parts of bleeding such as epistaxis, thrombocytopenia, functional uterine bleeding, threatened abortion, and unexplained hematuria. Distal bleeding also involves syndromes of failing to keep part deficient and cold fluids in interior, such as nocturia, enuresis, clear nose, sweating, cold tears, and leucorrhea, and excessive gastrointestinal bleeding caused by anti-plate and anticoagulant drugs, unexplained positive in the fecal occult blood test, and other modern clinical new problems. The indications of Huangtu Decoction include not only lower blood, defecation before blood, distant blood, hematemesis, epistaxis, and other diseases in traditional Chinese medicine, but also three types of clinical manifestations including bleeding, deficiency syndrome, and stagnant heat syndrome. In the clinic, Huangtu Decoction can be used to treat acute upper gastrointestinal bleeding, acute coronary syndrome complicated with acute upper gastrointestinal bleeding, bleeding events caused by excessive antiplatelet and anticoagulant drugs, unexplained positive in the fecal occult blood test, gastrointestinal tumor with bleeding, thrombocytopenia, and other acute and critical diseases. The dosage of Cooking Stove Earthkey, Rehmanniae Radix, and Asini Corii Colla in Huangtu Decoction is the key to hemostasis.
Humans
;
Gastrointestinal Hemorrhage/drug therapy*
;
Acute Coronary Syndrome
;
Epistaxis
;
Esophageal and Gastric Varices
;
Anticoagulants
;
Thrombocytopenia
;
Critical Care
5.Management of variceal hemorrhage: current status.
Chinese Medical Journal 2009;122(7):763-765
6.Practice guidance for the use of terlipressin for liver cirrhosis-related complications (2021).
Chinese Journal of Hepatology 2022;30(8):859-865
Liver cirrhosis is a major global health burden worldwide due to its high risk of morbidity and mortality. Role of terlipressin for the management of liver cirrhosis related complications has been recognized during recent years. This paper aims to develop evidence-based clinical practice guidance on the use of terlipressin for liver cirrhosis related complications. Hepatobiliary Study Group of Chinese Society of Gastroenterology of Chinese Medical Association and Hepatology Committee of Chinese Research Hospital Association have invited gastroenterologists, hepatologists, infectious disease specialists, surgeons, and clinical pharmacists to formulate the clinical practice guidance based on comprehensive literature review and experts' clinical experiences. Overall, 10 major statements regarding efficacy and safety of terlipressin in liver cirrhosis were proposed. Terlipressin can be beneficial for the management of cirrhotic patients with acute variceal bleeding and hepatorenal syndrome (HRS). However, the evidence regarding the use of terlipressin in cirrhotic patients with ascites, post-paracentesis circulatory dysfunction, and bacterial infections and in those undergoing hepatic resection and liver transplantation remains insufficient. Terlipressin-related adverse events, mainly including gastrointestinal symptoms, electrolyte disturbance, and cardiovascular and respiratory adverse events, should be closely monitored. The current clinical practice guidance supports the use of terlipressin for gastroesophageal variceal bleeding and HRS in liver cirrhosis. High-quality studies are needed to further clarify its potential effects in other liver cirrhosis related complications.
Electrolytes
;
Esophageal and Gastric Varices/drug therapy*
;
Gastrointestinal Hemorrhage/etiology*
;
Hepatorenal Syndrome/etiology*
;
Humans
;
Liver Cirrhosis/drug therapy*
;
Lypressin/adverse effects*
;
Terlipressin/adverse effects*
;
Vasoconstrictor Agents/adverse effects*
7.Efficacy of Repeated Arterial Infusion of Cisplatin and 5-Fluorouracil via a Percutaneously Implantable Port System in Advanced Hepatocellular Carcinoma.
Hee Gon SONG ; Han Chu LEE ; Byung Cheol SONG ; Young Hwa CHUNG ; Yung Sang LEE ; Hyun Ki YOON ; Kyu Bo SUNG ; Dong Jin SUH
The Korean Journal of Hepatology 2001;7(1):61-67
BACKGROUND/AIMS: A prospective study was performed to evaluate the efficacy of low dose administration of cisplatin (CDDP) and 5-fluorouracil (5-FU) by repeated arterial infusion via a percutaneously implantable port system (PIPS) for advanced hepatocellular carcinoma (phase II trial). METHODS: Ten patients with hepatocellular carcinoma belonging to TNM stage IV, but without extrahepatic spread, were enrolled. Nine patients had main portal vein thrombosis. All the patients were positive for HBsAg. Patients were repeatedly treated with an arterial infusion of CDDP and 5-FU (10 mg and 250 mg, respectively, for 5 hours on days 1-5) via a PIPS at four week intervals. The response was assessed by dynamic CT after two courses of chemotherapy. RESULTS: Insertion of PIPS was successful in 8 of 10 patients. Two patients could not receive a second course of chemotherapy because one died of progressive hepatic failure and the other developed local infection and pseudoaneurysm formation. All the remaining 6 patients exhibited tumor progression after two courses of chemotherapy. The median survival time was 89 days (range, 59-204). The causes of death were progressive hepatic failure in one patient and uncontrolled esophageal variceal bleeding in one patient. CONCLUSIONS: Arterial infusion chemotherapy with CDDP and 5-FU via a PIPS was not an effective treatment for patients with advanced hepatocellular carcinoma.
Aneurysm, False
;
Carcinoma, Hepatocellular*
;
Cause of Death
;
Cisplatin*
;
Drug Therapy
;
Esophageal and Gastric Varices
;
Fluorouracil*
;
Hepatitis B Surface Antigens
;
Humans
;
Liver Failure
;
Prospective Studies
;
Venous Thrombosis
8.Prevention of Esophageal Variceal Bleeding.
The Korean Journal of Gastroenterology 2010;56(3):155-167
Esophageal varices(EV) are present in 40% and 60% of Child-Pugh A and C patients, respectively when cirrhosis is diagnosed. EV bleeding is a life-threatening complication of liver cirrhosis with a high probability of recurrence. Treatment to prevent first EV bleeding or rebleeding is mandatory. In small EV with high risk of bleeding, nonselective beta-blockers should be used for the prevention of first variceal bleeding. For medium to large EV, nonselective beta-blockers or endoscopic variceal ligation (EVL) may be recommended to high risk varices. But, nonselective beta-blockers are the first treatment option to non-high risk varices and EVL is an alternative when nonselective beta-blockers are contraindicated or not tolerated. For the prevention of rebleeding, a combination of nonselective beta-blockers and EVL may be the best option. A great improvement in the prevention of variceal bleeding has emerged over the last years. However, further therapeutic options that combine higher efficacy, better tolerance and fewer side effects are needed.
Adrenergic beta-Antagonists/therapeutic use
;
Esophageal and Gastric Varices/drug therapy/*prevention & control
;
Gastrointestinal Hemorrhage/*etiology
;
Humans
;
Ligation
;
Portasystemic Shunt, Transjugular Intrahepatic
;
Sclerotherapy
9.Effects of isosorbide-5-mononitrate on esophageal manometry of cirrhotic patients with esophageal varices.
Xiang-fei LIN ; Jin-ming WU ; Xiu-ying LIN ; Min-xin CHEN ; Qi-huai ZHU ; Xiao-li WU
Chinese Journal of Hepatology 2005;13(8):611-612
Adult
;
Esophageal and Gastric Varices
;
drug therapy
;
etiology
;
physiopathology
;
Esophagus
;
physiopathology
;
Female
;
Humans
;
Isosorbide Dinitrate
;
analogs & derivatives
;
therapeutic use
;
Liver Cirrhosis
;
complications
;
physiopathology
;
Male
;
Manometry
;
Vasodilator Agents
;
therapeutic use
10.Inhibition of pathological angiogenesis of Chinese medicine against liver fibrosis.
Chinese journal of integrative medicine 2016;22(8):569-572
Pathological angiogenesis of liver which includes liver sinusoidal capillarization due to lose of fenestraes of liver sinusoidal endothelial cells (LSECs) and formation of new vascular, is a crucial mechanism responsible for origination and development of liver fifibrosis and closely involves in the development of cirrhosis and hepatic cancer. Anti-neovascularization medicine such as sorafenib can decrease portosystemic shunts, improve splanchnic hyperdynamic circulation, lower portal hypertension, while it can not be applied in clinic due to its serious toxic and side reactions. Chinese herbal formula can effectively inhibit pathological angiogenesis of liver, improve microcirculation of liver, and decrease the probability of gastrointestinal hemorrhage in cirrhotic patients. Different Chinese herbal formula are of different characteristics on inhibiting pathological angiogenesis in liver fifibrosis, which partly explains synergistic effect of different compatibility of Chinese materia medica and opens up good vista for Chinese medicine against liver fifibrosis through inhibiting angiogenesis.
Drugs, Chinese Herbal
;
pharmacology
;
therapeutic use
;
Esophageal and Gastric Varices
;
complications
;
drug therapy
;
Hemorrhage
;
complications
;
drug therapy
;
Humans
;
Liver Cirrhosis
;
complications
;
drug therapy
;
Microcirculation
;
drug effects
;
Neovascularization, Pathologic
;
complications
;
drug therapy